NEW YORK (GenomeWeb) – Charles River Laboratories said this week it will license its collection of patient-derived xenograft (PDX) tumors to InSphero. In addition, Charles River will use InSphero's proprietary 3D cell culture technology to extend and complement its preclinical services, using in vitro InSight tumor Microtissues derived from its existing PDX collection.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.